



## Prof. Dr. Clive G. Wilson

Research Professor, Strathclyde Institute of Pharmacy and Biomedical Sciences

**(Keynote Speaker)**

**Title:** Regional Drug Delivery in the Gut

**Abstract :** Oral drug delivery products can be stratified into a number of different technologies, according to the purpose of therapy. The starting point has generally been immediate release formulations but for some drugs, release in the stomach is undesirable. Line extensions often employ sustained or extended delivery formulations based on polymeric encapsulation of the drug. The most modern developments include positioned release technologies, which attempt a regional delivery to maximise effectiveness of the drug. The regional delivery systems have many challenges as in vitro testing may not reflect the conditions encountered by the formulation during the travel to the target. Moreover, interference with normal function must be minimal. Clinical testing may also give ambiguous results; physiological factors such as transit time and even anatomical and biochemical differences between individuals might be important variables to be considered. This lecture will explore some of the difficulties encountered in designing novel dosage forms and the testing in man.

# Prof. Dr. Clive G. Wilson

## Professional Biography

Clive Wilson is a Research Professor at Strathclyde University and recently retired as the J. P. Todd Chair in Pharmaceutics. He remains an active member of staff and was offered the post of Research Professor for the next four years. He is heavily involved in global pharmaceutical projects in the USA and Europe across industry and academic groups. He is a past-president of the European Union Federation for Pharmaceutical Sciences (EUFEPS). He serves on Senate of EUFEPs with interests in European training policy and education and on the EU COST action UNGAP management board. In August this year, he was invited to become Chief Scientific Officer of ReVana, a Queen's University Belfast spinout concerned with developing ocular implants for treatment of glaucoma and wet AMD. Major areas of research have been the study of the behaviour of drug formulations in man. With John Hardy in Medical Physics at Queen's Medical Centre and later Professor Davis in Pharmacy at Nottingham, he pioneered applications of scintigraphy in the study of drug absorption following oral, nasal, pulmonary and ophthalmic delivery. He has published more than 180 papers, seven books and over 100 reviews and book chapters and has supervised 64 Ph.D. and 1 M.D. student. He was made a Fellow of the Controlled Release Society in June 2010 and an Eminent Fellow of the Academy of Pharmaceutical Sciences in September 2011. In November 2017, he was awarded *doctor honoris causa* of Semmelweis University, Budapest, Hungary for work on oral drug absorption.